Last reviewed · How we verify
Paroxetine and Oxycodone
Paroxetine and Oxycodone is a Small molecule drug developed by Food and Drug Administration (FDA). It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Paroxetine and Oxycodone |
|---|---|
| Sponsor | Food and Drug Administration (FDA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) and an Opioid on Ventilation (PHASE1)
- Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation (PHASE1)
- Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery (NA)
- Influence of Oxycodone on Individuals Taking an SSRI (PHASE1)
- YouScript IMPACT Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paroxetine and Oxycodone CI brief — competitive landscape report
- Paroxetine and Oxycodone updates RSS · CI watch RSS
- Food and Drug Administration (FDA) portfolio CI
Frequently asked questions about Paroxetine and Oxycodone
What is Paroxetine and Oxycodone?
Who makes Paroxetine and Oxycodone?
What development phase is Paroxetine and Oxycodone in?
Related
- Manufacturer: Food and Drug Administration (FDA) — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing